Regeneron Pharmaceuticals (REGN)

• Market cap: $76.6B
• 1 day: 0.62%
• 5 days: 3.26%
• 1 month: 1.82%
• 3 months: -5.93%
• 6 months: -40.92%
• Year to date: -2.08%
• 1 year: -26.50%
• 5 years: 73.71%
• 10 years: 64.74%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Employees: 15,106

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

2% more call options, than puts

Call options by funds: $1.19B | Put options by funds: $1.17B

3% less repeat investments, than reductions

Existing positions increased: 459 | Existing positions reduced: 473

6.42% less ownership

Funds ownership: 92.2% [Q3] → 85.78% (-6.42%) [Q4]

8% less funds holding

Funds holding: 1,364 [Q3] → 1,252 (-112) [Q4]

25% less first-time investments, than exits

New positions opened: 152 | Existing positions closed: 203

36% less capital invested

Capital invested by funds: $104B [Q3] → $66B (-$37.8B) [Q4]

39% less funds holding in top 10

Funds holding in top 10: 23 [Q3] → 14 (-9) [Q4]

Research analyst outlook

10 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $165 76% downside
• Avg. target: $780 11% upside
• High target: $1,070 53% upside

10 analyst ratings

• positive: 5 50%
• neutral: 4 40%
• negative: 1 10%

Baird Brian Skorney 22% 1-year accuracy 5 / 23 met price target	8% upside $759	Neutral Maintained	5 Feb 2025
Leerink Partners David Risinger 36% 1-year accuracy 4 / 11 met price target	19% upside $834	Outperform Upgraded	5 Feb 2025
Citigroup Geoff Meacham 50% 1-year accuracy 15 / 30 met price target	7% upside $750	Neutral Maintained	28 Jan 2025
Piper Sandler Christopher Raymond 25% 1-year accuracy 8 / 32 met price target	45% upside $1,013	Overweight Maintained	27 Jan 2025
UBS Trung Huynh 57% 1-year accuracy 4 / 7 met price target	5% upside $738	Neutral Downgraded	16 Jan 2025